Alain Rolland is an executive with 25 years of international leadership experience in Pharmaceutical (Ciba Geigy, Galderma) and Biotech companies (GeneMedicine, Valentis, Vical). Until recently he was a Corporate Officer and Executive Vice President at Vical (San Diego, CA), a publicly traded 120- employee biopharmaceutical research and development company developing cancer immunotherapeutics and infectious disease vaccines. Before joining Vical in 2002, he was Senior Vice President, Preclinical R&D, and the Head of The Woodlands Center of Valentis, a biopharmaceutical delivery company formed in 1999 through the merger of GENEMEDICINE (The Woodlands, TX), Megabios (Burlingame, CA) and PolyMASC (London, UK). Prior to Valentis, he was first Director of Gene Delivery, then Vice President of Research at GENEMEDICINE from June 1993 to March 1999. From 1989 to 1993, Dr. Rolland was Head, Formulation Research at the R&D Center (CIRD) of Galderma International in France. From 1987 to 1988, he was a scientist at the Advanced Drug Delivery Research Center of Ciba Geigy Pharmaceuticals in the UK where he developed nanotechnologies for drug targeting. He has been responsible for leading and managing groups of more than 60 scientists and over the past two decades he has been involved in moving several products (small molecules, gene-based medicines and vaccines) through INDs into the clinic (through Phase 3) for the treatment of cancer, inflammation, cardiovascular, neuromuscular, and infectious diseases. He has participated in defining and implementing corporate strategies, has led R&D organizations and has provided leadership for the development of several products. He has also participated in partnering and intellectual property activities. He has successfully completed the Executive Business Education program on Transition to General Management at Columbia University, Graduate School of Business.
Dr. Rolland received his Pharm.D. (1981) and a degree (DEA) in Pharmacokinetics and Biopharmaceutics (1983) from Rennes University (France). He obtained his Ph.D. in Pharmaceutical Sciences (1987) from Rennes University after inventing, characterizing and developing a novel nanotechnology for targeting anticancer drugs to the liver that was evaluated in a Phase 1-2 clinical trial for the treatment of hepatocellular carcinoma. He has published over ninety scientific articles and book chapters, and he is the editor of three scientific books. He is a member of several scientific societies, including the American Controlled Release Society, the American Association of Pharmaceutical Scientists, and the American Society of Gene & Cell Therapy. He is the founding Editor-in-Chief of Current Pharmaceutical Biotechnology and an Editorial Board member of several Journals. He is an inventor of more than 20 international patents in the field of advanced drug delivery systems, drug/gene targeting and formulation. He is the recipient of the 2008 Fellowship award from the American Association of Pharmaceutical Scientists.